Key takeaways
Rybelsus (semaglutide) and Wegovy (semaglutide) are both medications that belong to the glucagon-like peptide-1 (GLP-1) receptor agonist class. They share the active ingredient semaglutide and are used to manage conditions related to weight and blood sugar, but there are a few key differences. Rybelsus is FDA-approved for treating Type 2 diabetes, while Wegovy is approved for long-term weight management in adults and children aged 12 and older with high body mass index (BMI). Rybelsus is taken orally once a day, whereas Wegovy is injected under the skin once a week. Both medications are only available as brand-name medications. Common side effects for both include nausea, vomiting, and diarrhea. Rybelsus and Wegovy can interact with oral medications by affecting their absorption; they can also raise the risk of low blood sugar when combined with diabetes medications. Both medications carry a risk of thyroid cancer and should not be used by individuals with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
